Background: The prevalence of SARS-COV2 in Libya is unclear; PCR is still under-performed. Although lockdown measures have been in place for weeks, there is no prevalence data to support the gradual lifting of such lockdowns. SARS-COV2 IgM/IgG is emerging as potential alternatives to PCR testing, and many counties and towns have undertaken such seroprevalence studies. Objective: Prevalence of SARS-COV2 in Misrata, Libya amongst the population as a whole. Materials and Methods: The study was prospective, cross-sectional, population-based, and age-stratified, to assess SARS-COV2 IgM/IgG in the population of Misrata. It was carried out between the 18th and 21st of April, 2020. Results: A representative sample of 897 participants was tested for SARS-COV2 IgM/IgG antibodies. 30 participants were positive for IgM or IgG indicating a prevalence of 3.4% (95% CI, 2.8% - 5.2%), with eight (0.9%) IgM positive and 22 (2.4%) IgG positive. Accordingly, 9075 (95% CI, 6586 - 14,170) people are estimated to have had a current or recent COVID-19 infection, symptomatic or asymptomatic. Conclusion and Recommendations: Serological testing as a diagnostic or surveillance tool may uncover a large proportion of asymptomatic individuals in the community, far outnumbering PCR. The authors highly recommend further precautionary public measures, as well as an ongoing surveillance programme to monitor the epidemiological trends of the disease in the city of Misrata and Libya in general.
References
[1]
Turner, K. (2020) Standardized Surveillance Case Definition and National Notification for 2019 Novel Coronavirus Disease (COVID-19). Council of State and Territorial Epidemiologists.
[2]
World Health Organization (2020) Immunity Passports in the Context of COVID-19. https://doi.org/10.15557/PiMR.2020.0024
[3]
Rothan, H.A. and Byrareddy, S.N. (2020) The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. Journal of Autoimmunity, 109, Article ID: 102433. https://doi.org/10.1016/j.jaut.2020.102433
[4]
Kolifarhood, G., et al. (2020) Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. Archives of Academic Emergency Medicine, 8, e41.
[5]
Chadwick, L. (2020) Coronavirus: Antibody Tests “Will Be Crucial” in Determining When to Lift Lockdowns. EURONEWS.
[6]
National Center for Disease Control and Prevention (2020) Coronavirus Disease 2019 (COVID-19)—Cases, Data & Surveillance—Purpose and Methods.
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/purpose-methods.html
[7]
Worldometer (2020) World/Countries/South Korea Coronavirus Cases.
[8]
Peto, J. (2020) COVID-19 Mass Testing Facilities Could End the Epidemic Rapidly. BMJ, 368, m1163. https://doi.org/10.1136/bmj.m1163
Gudbjartsson, D.F., et al. (2020) Spread of SARS-CoV-2 in the Icelandic Population. New England Journal of Medicine, 382, 2302-2315.
[11]
World Health Organization (2020) Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020.
[12]
Padoan, A., et al. (2020) Analytical Performances of a Chemiluminescence Immunoassay for SARS-CoV-2 IgM/IgG and Antibody Kinetics. Clinical Chemistry and Laboratory Medicine, 58, 1081-1088. https://doi.org/10.1515/cclm-2020-0443
[13]
Lippi, G., et al. (2020) Assessment of Immune Response to SARS-CoV-2 with Fully Automated MAGLUMI 2019-nCoV IgG and IgM Chemiluminescence Immunoassays. Clinical Chemistry and Laboratory Medicine, 58, 1156-1159.
https://doi.org/10.1515/cclm-2020-0473
[14]
Amanat, F., et al. (2020) A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans. Nature Medicine, 1-4.
[15]
Gronvall, G., et al. (2020) Developing a National Strategy for Serology (Antibody Testing) in the United States. The Johns Hopkins Center for Health Security, 1-38.
[16]
World Health Organization (2020) WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19.
[17]
Sood, N., Simon, P., Ebner, P., Eichner, D., Reynolds, J., Bendavid, E. and Bhattacharya, J. (2020) Seroprevalence of SARS-CoV-2-Specific Antibodies among Adults in Los Angeles County, California, on April 10-11, 2020. JAMA, 323, 2425-2427.
https://doi.org/10.1001/jama.2020.8279
[18]
Hopper, L. (2020) Early Antibody Testing Suggests COVID-19 Infections in L.A. County Greatly Exceed Documented Cases. USC News.
[19]
Andrea Crisanti, A.C. (2020) In One Italian Town, We Showed Mass Testing Could Eradicate the Coronavirus. The Guardian.
[20]
Zorzoli, M. (2020) I nuovi dati di Robbio, unico paese italiano a fare il test sull’immunità a tutti i cittadini. Business Insider Italia.
[21]
Streeck, H., et al. (2020) Vorläufiges Ergebnis und Schlussfolgerungen der COVID- 19 Case-Cluster-Study (Gemeinde Gangelt).
[22]
Shakiba, M., et al. (2020) Seroprevalence of COVID-19 Virus Infection in Guilan Province, Iran. https://doi.org/10.1101/2020.04.26.20079244
[23]
Doi, A., et al. (2020) Estimation of Seroprevalence of Novel Coronavirus Disease (COVID-19) Using Preserved Serum at an Outpatient Setting in Kobe, Japan: A Cross-Sectional Study. https://doi.org/10.1101/2020.04.26.20079822
[24]
World Health Organization (2020) Population-Based Age-Stratified Seroepidemiological Investigation Protocol for COVID-19 Virus Infection.
Jain, S., et al. (2015) Community-Acquired Pneumonia Requiring Hospitalization among US Adults. New England Journal of Medicine, 373, 415-427.
https://doi.org/10.1056/NEJMoa1500245
